Brookings scholar warns of CLARITY Act risks: US CFTC could face an absence of substantive regulatory powers
Odaily reported that Aaron Klein, a scholar at the Brookings Institution in the United States, has issued a warning that as Congress reviews digital asset legislation, the Commodity Futures Trading Commission (CFTC) may encounter issues regarding insufficient regulatory capacity as it seeks to expand its oversight of digital assets. Aaron Klein pointed out that the CFTC was originally established to regulate the commodity futures markets and was not designed for the scale of responsibilities proposed under the current crypto regulations. A lack of additional personnel, funding, and expertise could result in a situation where the agency has regulatory authority but lacks effective supervision. The recent loss of staff and organizational adjustments at the CFTC have weakened its regulatory capacity, and expanded responsibilities could lead to a recurrence of regulatory failures seen during past financial crises. If crypto oversight responsibilities are spread across multiple agencies, it could create delays and confusion, repeating the execution shortcomings witnessed during the Dodd-Frank era.
Aaron Klein criticized accusations that financial regulation is influenced by politics, emphasizing that enforcement should be independent from the White House or any political figures. He called for greater accountability and measures to prevent financial misconduct. Klein suggested that the SEC and CFTC should enhance coordination and possibly even merge to improve regulatory efficiency for digital assets and prediction markets. In the short term, sharing office space could facilitate collaboration better than mere formal agreements. (CoinDesk)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Roche (RHHBY.US) weight loss injection shows positive mid-term trial results: average weight loss of 15.5% over 48 weeks, blood sugar levels drop by 2.65%.
The experimental weight-loss injection enicepatide simultaneously lowered blood sugar and body weight in overweight or obese patients with type 2 diabetes during a mid-stage clinical trial.
SPAC company Silicon Valley Acquisition II (SVATU.US) applies for US stock IPO, aiming to raise up to 220 millions USD.
The blank-check company (SPAC) Silicon Valley Acquisition II submitted a filing to the U.S. Securities and Exchange Commission (SEC) on Monday, planning to raise up to 220 millions USD through an initial public offering (IPO).
China’s gold imports exceeded 1,000 tons by August, surpassing the total for all of 2025.

Africa Bitcoin Corp CEO Warren Wheatley resigns effective Sept. 21
